Patients could soon have access to a new injectable drug to treat atopic dermatitis, the most common form of eczema. The drug, lebrikizumab, proved effective in teenagers and adults in two clinical trials just published in the New England Journal of Medicine. “Across both of these pivotal studies for atopic dermatitis, lebrikizumab was highly effective, with a subset of patients responding quite early and then experiencing very durable responses up until week 16 in the initial phase of the study,” said lead researcher Dr. Jonathan Silverberg. He is an associate professor of dermatology at George Washington University School of Medicine & Health Sciences in Washington, D.C. Subsequent data has shown a good response among patients out to a year, he added. Based on these results, the U.S. Food and Drug Administration could approve lebrikizumab within a matter of months, Silverberg said. “We’re hoping that by mid-2023 that this will be FDA-approved and available to us to use, which is very exciting to have another highly effective option on the horizon,” he said. Lebrikizumab is an injectable monoclonal antibody designed to target interleukin-13, a biochemical expressed by immune cells that promotes an inflammatory response in the body. “It increases inflammation within the skin. It can increase or amplify the sensation of itch,” Silverberg said of interleukin-13. “And it also can lead to disruption of the skin… read on > read on >

















